Evidence map›Paper›PMID 37573004›Full record

ReviewBiological psychiatry2024

Clinical and Preclinical Evidence for Gut Microbiome Mechanisms in Substance Use Disorders.

Rebecca S Hofford, Drew D Kiraly

Abstract readReview
In one paragraph

Review in Biological psychiatry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Trial
  2. GutGut microbes · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Rebecca S HoffordDepartment of Physiology & Pharmacology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina.
Drew D KiralyDepartment of Physiology & Pharmacology, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina; Department of Psychiatry, Wake Forest University School of Medicine, Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina. Electronic address: dkiraly@wakehealth.edu.

Funding

Targeting the host metabolome to reverse drug-induced epigenetic changesDP1DA051551 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KIRALY, DREW · 2020 to 2024
$2.8M
Targeting gut brain-signaling to reduce cocaine seeking behaviorsR01DA056592 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Drew Kiraly · 2023 to 2026
$2.7M
Defining the role of short-chain fatty acids in adolescent opioid reinforcement and epigenetic regulationK01DA050906 · NIDA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HOFFORD, REBECCA · 2021 to 2025
$829k
NIDA NIH HHS DP1 DA051551NIDA NIH HHS K01 DA050906NIDA NIH HHS R01 DA056592
6 · The paper itself

Abstract

Substance use disorders are a set of recalcitrant neuropsychiatric conditions that cause tremendous morbidity and mortality and are among the leading causes of loss of disability-adjusted life years worldwide. While each specific substance use disorder is driven by problematic use of a different substance, they all share a similar pattern of escalating and out-of-control substance use, continued use despite negative consequences, and a remitting/relapsing pattern over time. Despite significant advances in our understanding of the neurobiology of these conditions, current treatment options remain few and are ineffective for too many individuals. In recent years, there has been a rapidly growing body of literature demonstrating that the resident population of microbes in the gastrointestinal tract, collectively called the gut microbiome, plays an important role in modulating brain and behavior in preclinical and clinical studies of psychiatric disease. While these findings have not yet been translated into clinical practice, this remains an important and exciting avenue for translational research. In this review, we highlight the current state of microbiome-brain research within the substance use field with a focus on both clinical and preclinical studies. We also discuss potential neurobiological mechanisms underlying microbiome effects on models of substance use disorder and propose future directions to bring these findings from bench to bedside.

Indexed as

Gastrointestinal MicrobiomeSubstance-Related DisordersBrainGastrointestinal TractHumansAlcohol use disorderEpigeneticsGut-brainMicrobiomeNeuroimmuneSubstance use disorder

Identifiers

PMID37573004
PMCPMC10884738

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.